Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

T. D. Kim; D. Rea; M. Schwarz; P. Grille; F. E. Nicolini; G. Rosti; L. Levato; F. J. Giles; H. Dombret; T. Mirault; H. Labussière; R. Lindhorst; W. Haverkamp; I. Buschmann; B. Dörken; P. D. Le Coutre

doi:10.1038/leu.2013.70

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

T. D. Kim, D. Rea, M. Schwarz, P. Grille, F. E. Nicolini, G. Rosti, L. Levato, F. J. Giles, H. Dombret, T. Mirault, H. Labussière, R. Lindhorst, W. Haverkamp, I. Buschmann, B. Dörken, P. D. Le Coutre^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

194 Scopus citations

Abstract

Several retrospective studies have described the clinical manifestation of peripheral artery occlusive disease (PAOD) in patients receiving nilotinib. We thus prospectively screened for PAOD in patients with chronic phase chronic myeloid leukemia (CP CML) being treated with tyrosine kinase inhibitors (TKI), including imatinib and nilotinib. One hundred and fifty-nine consecutive patients were evaluated for clinical and biochemical risk factors for cardiovascular disease. Non-invasive assessment for PAOD included determination of the ankle-brachial index (ABI) and duplex ultrasonography. A second cohort consisted of patients with clinically manifest PAOD recruited from additional collaborating centers. Pathological ABI were significantly more frequent in patients on first-line nilotinib (7 of 27; 26%) and in patients on second-line nilotinib (10 of 28; 35.7%) as compared with patients on first-line imatinib (3 of 48; 6.3%). Clinically manifest PAOD was identified in five patients, all with current or previous nilotinib exposure only. Relative risk for PAOD determined by a pathological ABI in first-line nilotinib-treated patients as compared with first-line imatinib-treated patients was 10.3. PAOD is more frequently observed in patients receiving nilotinib as compared with imatinib. Owing to the severe nature of clinically manifest PAOD, longitudinal non-invasive monitoring and careful assessment of risk factors is warranted.

Original language	English (US)
Pages (from-to)	1316-1321
Number of pages	6
Journal	Leukemia
Volume	27
Issue number	6
DOIs	https://doi.org/10.1038/leu.2013.70
State	Published - Jun 2013

Funding

TDK, MS, PG, LL, HD, TM, HL, RL, WH, IB and BD declare no conflict of interest. DR received honoraria from Teva, Novartis and BMS. FEN was a consultant for Novartis, Ariad and Teva. He received lecture fees from BMS, Novartis, Ariad and Teva and received advisory board honoraria from Novartis, Ariad, Teva and Pfizer. GR received honoraria from Novartis, BMS, Pfizer and Roche. FJG is a consultant for and received research funding from Novartis. PDLC received honoraria from Novartis, BMS, Pfizer and Ariad. He also received research funding from Novartis.

Keywords

chronic myeloid leukemia
imatinib
nilotinib
peripheral artery occlusive disease
tyrosine kinase inhibitor

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/leu.2013.70

Cite this

Kim, T. D., Rea, D., Schwarz, M., Grille, P., Nicolini, F. E., Rosti, G., Levato, L., Giles, F. J., Dombret, H., Mirault, T., Labussière, H., Lindhorst, R., Haverkamp, W., Buschmann, I., Dörken, B., & Le Coutre, P. D. (2013). Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib. Leukemia, 27(6), 1316-1321. https://doi.org/10.1038/leu.2013.70

@article{da8d866a231144429f1416f1df9d6b9c,

title = "Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib",

abstract = "Several retrospective studies have described the clinical manifestation of peripheral artery occlusive disease (PAOD) in patients receiving nilotinib. We thus prospectively screened for PAOD in patients with chronic phase chronic myeloid leukemia (CP CML) being treated with tyrosine kinase inhibitors (TKI), including imatinib and nilotinib. One hundred and fifty-nine consecutive patients were evaluated for clinical and biochemical risk factors for cardiovascular disease. Non-invasive assessment for PAOD included determination of the ankle-brachial index (ABI) and duplex ultrasonography. A second cohort consisted of patients with clinically manifest PAOD recruited from additional collaborating centers. Pathological ABI were significantly more frequent in patients on first-line nilotinib (7 of 27; 26%) and in patients on second-line nilotinib (10 of 28; 35.7%) as compared with patients on first-line imatinib (3 of 48; 6.3%). Clinically manifest PAOD was identified in five patients, all with current or previous nilotinib exposure only. Relative risk for PAOD determined by a pathological ABI in first-line nilotinib-treated patients as compared with first-line imatinib-treated patients was 10.3. PAOD is more frequently observed in patients receiving nilotinib as compared with imatinib. Owing to the severe nature of clinically manifest PAOD, longitudinal non-invasive monitoring and careful assessment of risk factors is warranted.",

keywords = "chronic myeloid leukemia, imatinib, nilotinib, peripheral artery occlusive disease, tyrosine kinase inhibitor",

author = "Kim, {T. D.} and D. Rea and M. Schwarz and P. Grille and Nicolini, {F. E.} and G. Rosti and L. Levato and Giles, {F. J.} and H. Dombret and T. Mirault and H. Labussi{\`e}re and R. Lindhorst and W. Haverkamp and I. Buschmann and B. D{\"o}rken and {Le Coutre}, {P. D.}",

note = "Funding Information: TDK, MS, PG, LL, HD, TM, HL, RL, WH, IB and BD declare no conflict of interest. DR received honoraria from Teva, Novartis and BMS. FEN was a consultant for Novartis, Ariad and Teva. He received lecture fees from BMS, Novartis, Ariad and Teva and received advisory board honoraria from Novartis, Ariad, Teva and Pfizer. GR received honoraria from Novartis, BMS, Pfizer and Roche. FJG is a consultant for and received research funding from Novartis. PDLC received honoraria from Novartis, BMS, Pfizer and Ariad. He also received research funding from Novartis.",

year = "2013",

month = jun,

doi = "10.1038/leu.2013.70",

language = "English (US)",

volume = "27",

pages = "1316--1321",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "6",

}

Kim, TD, Rea, D, Schwarz, M, Grille, P, Nicolini, FE, Rosti, G, Levato, L, Giles, FJ, Dombret, H, Mirault, T, Labussière, H, Lindhorst, R, Haverkamp, W, Buschmann, I, Dörken, B & Le Coutre, PD 2013, 'Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib', Leukemia, vol. 27, no. 6, pp. 1316-1321. https://doi.org/10.1038/leu.2013.70

TY - JOUR

T1 - Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

AU - Kim, T. D.

AU - Rea, D.

AU - Schwarz, M.

AU - Grille, P.

AU - Nicolini, F. E.

AU - Rosti, G.

AU - Levato, L.

AU - Giles, F. J.

AU - Dombret, H.

AU - Mirault, T.

AU - Labussière, H.

AU - Lindhorst, R.

AU - Haverkamp, W.

AU - Buschmann, I.

AU - Dörken, B.

AU - Le Coutre, P. D.

N1 - Funding Information: TDK, MS, PG, LL, HD, TM, HL, RL, WH, IB and BD declare no conflict of interest. DR received honoraria from Teva, Novartis and BMS. FEN was a consultant for Novartis, Ariad and Teva. He received lecture fees from BMS, Novartis, Ariad and Teva and received advisory board honoraria from Novartis, Ariad, Teva and Pfizer. GR received honoraria from Novartis, BMS, Pfizer and Roche. FJG is a consultant for and received research funding from Novartis. PDLC received honoraria from Novartis, BMS, Pfizer and Ariad. He also received research funding from Novartis.

PY - 2013/6

Y1 - 2013/6

N2 - Several retrospective studies have described the clinical manifestation of peripheral artery occlusive disease (PAOD) in patients receiving nilotinib. We thus prospectively screened for PAOD in patients with chronic phase chronic myeloid leukemia (CP CML) being treated with tyrosine kinase inhibitors (TKI), including imatinib and nilotinib. One hundred and fifty-nine consecutive patients were evaluated for clinical and biochemical risk factors for cardiovascular disease. Non-invasive assessment for PAOD included determination of the ankle-brachial index (ABI) and duplex ultrasonography. A second cohort consisted of patients with clinically manifest PAOD recruited from additional collaborating centers. Pathological ABI were significantly more frequent in patients on first-line nilotinib (7 of 27; 26%) and in patients on second-line nilotinib (10 of 28; 35.7%) as compared with patients on first-line imatinib (3 of 48; 6.3%). Clinically manifest PAOD was identified in five patients, all with current or previous nilotinib exposure only. Relative risk for PAOD determined by a pathological ABI in first-line nilotinib-treated patients as compared with first-line imatinib-treated patients was 10.3. PAOD is more frequently observed in patients receiving nilotinib as compared with imatinib. Owing to the severe nature of clinically manifest PAOD, longitudinal non-invasive monitoring and careful assessment of risk factors is warranted.

AB - Several retrospective studies have described the clinical manifestation of peripheral artery occlusive disease (PAOD) in patients receiving nilotinib. We thus prospectively screened for PAOD in patients with chronic phase chronic myeloid leukemia (CP CML) being treated with tyrosine kinase inhibitors (TKI), including imatinib and nilotinib. One hundred and fifty-nine consecutive patients were evaluated for clinical and biochemical risk factors for cardiovascular disease. Non-invasive assessment for PAOD included determination of the ankle-brachial index (ABI) and duplex ultrasonography. A second cohort consisted of patients with clinically manifest PAOD recruited from additional collaborating centers. Pathological ABI were significantly more frequent in patients on first-line nilotinib (7 of 27; 26%) and in patients on second-line nilotinib (10 of 28; 35.7%) as compared with patients on first-line imatinib (3 of 48; 6.3%). Clinically manifest PAOD was identified in five patients, all with current or previous nilotinib exposure only. Relative risk for PAOD determined by a pathological ABI in first-line nilotinib-treated patients as compared with first-line imatinib-treated patients was 10.3. PAOD is more frequently observed in patients receiving nilotinib as compared with imatinib. Owing to the severe nature of clinically manifest PAOD, longitudinal non-invasive monitoring and careful assessment of risk factors is warranted.

KW - chronic myeloid leukemia

KW - imatinib

KW - nilotinib

KW - peripheral artery occlusive disease

KW - tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84878910858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878910858&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.70

DO - 10.1038/leu.2013.70

M3 - Article

C2 - 23459449

AN - SCOPUS:84878910858

SN - 0887-6924

VL - 27

SP - 1316

EP - 1321

JO - Leukemia

JF - Leukemia

IS - 6

ER -

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this